BMY | Bristol-Myers Squibb Company Stock Overview

(Stock Exchange: NYSE)

Day's Range	59.37 - 61.64
52 Week Range	39.35 - 63.33
Beta	0.39
Implied Volatility	39.97%
IV Rank	61.40%
Day's Volume	7,692,759
Average Volume	11,683,822
Shares Outstanding	2,034,760,000
Market Cap	124,100,012,400
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1972-06-01

Valuation
Profitability
Growth
Health
P/E Ratio	-13.83
Forward P/E Ratio	8.02
EPS	-4.41
1YR Price Target	80.00
Dividend Yield	4.67%
Dividend Per Share	1.64
Dividend ExDate	2023-04-06
Dividend PayDate	2023-05-01
Employees	34,100
Country	USA
Website	BMY

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

BMY's peers: ABBV, ABT, AMGN, AMRN, AZN, BIIB, MRK, GILD, JNJ, LLY, PFE, GRFS, GSK, NVS, OGN, SNY, SCLX

*Chart delayed

Analyzing fundamentals for BMY we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see BMY Fundamentals page.

Watching at BMY technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BMY Technicals page.